Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy

Appointment strengthens Artis platform strategy in nucleic acid medicines in connection with pending Syngoi acquisition

SAN DIEGO–(BUSINESS WIRE)–Artis BioSolutions today announced the appointment of Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer, effective February 9, 2026. Dr. Broderick will lead scientific strategy, advocacy and innovation initiatives across the Artis platform, supporting the company’s mission to build an integrated ecosystem for the development and manufacturing of next-generation genetic medicines.

As demand continues to grow for high-quality technologies enabling advanced therapies, Artis is expanding its leadership team to accelerate innovation and strengthen its scientific capabilities. Dr. Broderick is a seasoned life sciences executive with more than 25 years of global experience and deep expertise in nucleic acid medicine, DNA- and RNA-based vaccine development, and drug delivery innovation. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences, where she led the strategic growth of the company’s innovation engine through internal development initiatives and external licensing opportunities.

Previously, Dr. Broderick served as Senior Vice President of R&D at Inovio Pharmaceuticals, where she led a multidisciplinary team focused on DNA-based vaccines, therapeutics, and delivery technologies. During her tenure, she advanced multiple clinical-stage programs, including overseeing the development of a DNA-based COVID-19 vaccine through Phase 3 testing. She also served as Principal Investigator on the first Lassa Fever vaccine trial conducted in West Africa. Additionally, Dr. Broderick was instrumental in securing more than $100 million in non-dilutive funding from U.S. government agencies, CEPI, the WHO, the Gates Foundation, and other global partners.

“Kate’s scientific depth and proven leadership in nucleic acid technologies make her uniquely positioned to help drive our synthetic DNA strategy forward,” said Brian Neel, Co-Founder and CEO of Artis BioSolutions. “As we move toward closing the Syngoi transaction, her experience scaling innovation platforms and translating advanced DNA technologies into clinical programs will be critical to our integration and long-term growth.”

Dr. Broderick earned her Ph.D. in Molecular Genetics from the University of Glasgow and completed her postdoctoral training at the University of California, San Diego, with a focus on drug development. She has authored more than 100 peer-reviewed publications and is an inventor on multiple patents related to nucleic acid-based vaccine and therapeutic technologies.

“Joining Artis at this pivotal moment represents an opportunity to help shape the future of synthetic DNA and its role in unlocking next-generation therapies,” said Dr. Broderick. “I look forward to working across Artis, Syngoi, and Landmark Bio to accelerate innovation and strengthen the infrastructure supporting the new wave of life changing genetic medicines.”

The proposed acquisition of Syngoi Technologies is expected to close in the first quarter of 2026, subject to customary closing conditions. Landmark Bio was Artis BioSolutions’ inaugural acquisition, establishing the company’s foundation in integrated development and GMP manufacturing capabilities to support advanced therapies.

About Artis BioSolutions

Artis BioSolutions is a San Diego-based platform company focused on building and scaling differentiated capabilities to support the development and manufacturing of advanced therapies. Through a growing global footprint, including Landmark Bio in Boston, Artis partners with biotech and pharmaceutical companies to provide integrated solutions across the lifecycle of advanced therapeutic programs.

About Landmark Bio

Landmark Bio, LLC, headquartered in Watertown, Massachusetts, provides integrated development and GMP manufacturing solutions to support advanced therapy programs. Founded by leading academic and industry partners, Landmark combines deep drug development expertise with next-generation manufacturing capabilities. Landmark Bio is part of Artis BioSolutions.

About Syngoi Technologies

Syngoi Technologies is a biotechnology company based in Bilbao, Spain, focused on innovative synthetic DNA technologies for use in advanced therapies. The company has developed a differentiated platform designed to improve how DNA inputs are produced and supplied, supporting emerging therapeutic modalities and next-generation manufacturing approaches.

Contacts

inquiries@artisbiosolutions.com